IgA Nephropathy

Data from multiple presentations at ASN Kidney Week 2023 offer insight into the effects of atacicept in patients with IgA nephropathy as well as the design of the phase 3 trial, which is currently enrolling.

Preliminary data from the open-label RUBY-3 trial were presented at the American Society of Nephrology Kidney Week 2023.

The 2-year data from the PROTECT study confirms the sustained benefit of sparsentan in patients with IgA nephropathy.

Presented at ASN Kidney Week 2023, results of the ENVISION trial provide the latest insight into effects of sibeprenlimab in management of IgA nephropathy as the nephrology community awaits the results of its ongoing phase 3 trial.

Atrasentan demonstrated superiority versus placebo for reduction in proteinuria through 36 weeks.

Patients with IgA nephropathy experienced nearly 30% proteinuria reduction after 6 months of treatment with SGLT2 inhibitors.

Findings showed the probability of achieving total remission was significantly greater in the corticosteroid pulse group compared to the oral corticosteroid group.

Interim results from the phase 3 APPLAUSE-IgAN study showed a statistically significant reduction in proteinuria among patients treated with iptacopan compared to placebo.

Positive findings from NefIgArd demonstrated budesonide’s ability to modulate the intestinal immune network responsible for IgA production.

Phase 3 data show a significant clinical profile associated with durable reductions in IgA nephropathy biomarkers among patients treated with Nefecon.

Discussing the key differences in the results of ISCHEMIA and ISCHEMIA-CKD, which examined whether the use of invasive or conservative strategies was more effective for patients with ischemic heart disease.

Topline data from Rigel Pharmaceuticals’ proof-of-concept Phase 2 study of fostamatinib in patients with IgA nephropathy, or Berger’s disease, were announced today.